Veru Inc. (NASDAQ: VERU), the stock jumped 21.79% to $7.74 in the premarket session after a biopharmaceutical oncology corporation focused on the production of new cancer treatment drugs, today reported high net sales and gross profit for its fourth quarter and full-year ended September 30, 2020, for fiscal 2020.
4th-quarter: YOY highlights
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
From $8.7 million, net sales rose 35% to $11.7 million years over year.
FC2 net prescription revenue increased 87% from $4.7 million to $8.7 million.
The company’s Gross profit soared 64% from $5.8 million to $9.6 million. It’s Gross margin rose from 67% of net revenue to 81% of net revenue.
The net loss was $11.3 million, with a non-cash impairment fee of $14.1 million relating to intangible assets. Net revenue was $2.8 million with an operating deficit of $1.5 million, minus the non-cash impairment fee.
Before the fee for non-cash impairment, the net loss was $11.8 million, or $0.17 per share, compared to $3.1 million, or $0.05 per share.
Full-year: YOY Highlights
From $31.8 million, net sales grew 34% to $42.6 million.
Company sales of prescription FC2 soared 93% from $14.1 million to $27.1 million. Its Gross profit gained 42% from $21.7 million to $30.8 million.
Gross margin rose from 68% of net sales to 72% of net revenue.
The net loss was $14.7 million, with a non-cash impairment fee of $14.1 million relating to intangible assets.
Compared to $12.0 million, or $0.19 per share, the net loss, which contains the non-cash impairment fee, was $19.0 million, or $0.28 per share.
